|Mr. Brian A. Markison||Chairman, Pres & CEO||1.11M||N/A||1959|
|Mr. Andrew J. Einhorn||Chief Financial Officer||505.07k||N/A||1960|
|Dr. Tina Marie deVries||Exec. VP of R&D||551.38k||N/A||1961|
|Mr. James D. Schaub||Exec. VP & COO||N/A||N/A||1982|
|Mr. Christopher A. Klein||Gen. Counsel & Sec.||N/A||N/A||1964|
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Osmotica Pharmaceuticals plc’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 4; Compensation: 8.